REMS vs DEXA: The Radiation-Free Bone Scan Explained

What exactly is a REMS bone scan and how does it differ from DEXA?

REMS (Radiofrequency Echographic Multi Spectrometry) is a radiation-free ultrasound scan of the bone, whereas DEXA (dual-energy X-ray absorptiometry) measures bone density using a small dose of X-rays. Both look at the same target — the bone mineral density of your spine and hip — and both produce a T-score, the standard number used to classify normal bone, low bone mass (osteopenia) and osteoporosis.

The difference is in the physics. DEXA passes two X-ray energies through the bone and measures how much is absorbed. REMS instead analyses the raw radio-frequency ultrasound signals that bounce back from the bone, comparing them against reference models to estimate density and bone quality. A 2025 systematic review describes REMS as non-ionising and radiation-free, using these raw ultrasound signals rather than ionising radiation Diagnostics, 2025.

In short: same question (how strong is your bone?), two different tools for answering it. You can read a fuller technical explainer on our REMS technology page.

How does the radiation-free aspect of REMS actually matter in practice?

It matters most for repeat scanning. Because REMS uses ultrasound rather than X-rays, there is no radiation dose involved, so it can be repeated more freely when you need to track bone density over time — for example while on a treatment that affects bone, through menopause, or after a meaningful change in weight or activity.

DEXA's radiation dose is low, and a single DEXA is not something to be anxious about. But the radiation-free nature of REMS removes one of the practical brakes on frequent monitoring, and it makes screening more comfortable for groups who are understandably radiation-cautious — younger people and women in early pregnancy among them, both of which appear in proposed practice parameters as situations where REMS may be considered Bone & Joint Open, 2025.

The honest framing: radiation-free is a genuine practical advantage for access and monitoring — but it is a property of the method, not proof that the result is more accurate. Accuracy is a separate question, addressed next.

How accurate is REMS compared to DEXA for detecting osteoporosis?

In many study populations REMS agrees well with DEXA, but the agreement is not uniform — it depends heavily on who is being scanned. A 2025 systematic review pooling 17 studies and 11,664 patients reported sensitivity of roughly 70% to 91.7% and specificity of 73.2% to 95.5%, with a summary diagnostic concordance range of about 63.6% to 90% against DEXA Diagnostics, 2025. That 63.6%–90% figure is the review's summary range; across all the individual studies the spread is wider, which is exactly why a single headline accuracy number can mislead.

Some individual studies report higher agreement still: one widely cited dataset found 88.8% concordance at the lumbar spine and 88.2% at the femoral neck Diagnostics, 2023. A 2025 narrative review also notes that REMS-versus-DEXA correlation is frequently above 0.90 Cureus, 2025 — though correlation (do the two numbers move together?) is not the same as diagnostic agreement (do they assign the same person to the same category?), so the two figures should not be conflated.

The fair summary: REMS is a credible measure of bone density that tracks DEXA closely in typical patients, but it is not a like-for-like swap in every population, and the evidence base — while growing — still sits below DEXA's decades of validation.

Where does REMS outperform DEXA — and where does it fall short?

REMS shows particular promise where DEXA is technically difficult or distorted — but it has clear weak spots that must not be glossed over.

DEXA can be thrown off by anything dense sitting over the bone: spinal hardware, advanced arthritis, vertebral fractures, or hip replacements. In these situations the standard X-ray read can over-state bone density and falsely reassure. Proposed practice parameters list scenarios where REMS may be preferred over DEXA, including people who are bedridden or immobilised, those with spinal instrumentation (fusion rods and screws), vertebroplasty or kyphoplasty, severe scoliosis or advanced degenerative change, the first trimester of pregnancy, and younger patients where reducing radiation matters Bone & Joint Open, 2025. (Note these are proposed parameters, not an adopted national standard.)

A single illustrative case report describes a 75-year-old woman with bilateral hip replacements and a normal DEXA T-score of −0.9, yet a REMS fragility score suggestive of osteoporosis — alongside actual bilateral sacral insufficiency fractures that the DEXA had not flagged Cureus, 2026. This is a single case (n=1), the lowest tier of evidence, so it illustrates how a DEXA artefact can occur in patients with prosthetics — it is not proof that REMS is generally more accurate.

What does the REMS Fragility Score tell you that a DEXA T-score does not?

The Fragility Score is a REMS-derived indicator of fracture risk, designed to add information beyond density alone. A T-score tells you how your bone density compares with a young-adult reference; evidence suggests the Fragility Score aims to flag people at raised fracture risk even when their density looks borderline.

In a study of 1,989 participants followed over a period reaching up to 5 years (mean follow-up was around 3.5 years), the REMS Fragility Score predicted incident fragility fractures better than the DEXA T-score in that cohort: area-under-the-curve of 0.811 in women and 0.780 in men at the lumbar spine, versus 0.678 and 0.635 respectively for the DEXA T-score Aging Clin Exp Res, 2023.

This is encouraging — but it is one cohort study, not settled consensus, and it sits alongside national guidance that does not yet endorse REMS for diagnosis. Early data indicate the Fragility Score may add useful predictive information; it should be read as a promising signal rather than a proven replacement for established fracture-risk tools.

Is REMS recommended or approved for osteoporosis diagnosis in the UK?

No — and this is the most important point to be clear about. The 2024 UK clinical guideline from the National Osteoporosis Guideline Group (NOGG) makes a strong recommendation that quantitative ultrasound, IBEX bone health and Radiofrequency Echographic Multi-Spectrometry are not recommended for the diagnosis of osteoporosis, and names DEXA at the femoral neck as the reference technology because of its higher predictive value for fracture Archives of Osteoporosis, NOGG 2024.

That is a clinical-guidance position about diagnosis. It does not, on its own, say anything about a device's regulatory status, and none of the evidence here establishes UK regulatory approval, CE/UKCA marking, NHS provision or pricing — so we make no claims on those points.

What this means in practice: if you need a diagnostic decision in the UK, DEXA remains the reference standard your clinician will rely on. REMS is best understood as a complementary, radiation-free screening and monitoring tool — valuable for access, for repeat tracking, and for situations where DEXA is difficult — rather than a UK-recommended diagnostic replacement. We think being upfront about this matters more than overselling the technology; you can read our position on the evidence on our scientific approach page.

Who is most likely to benefit from a REMS scan over a DEXA scan?

The clearest beneficiaries are people for whom DEXA is unavailable, unreliable, or best avoided. Based on the proposed practice parameters and the wider evidence, REMS may particularly suit:

• People needing frequent monitoring, where avoiding repeated radiation is an advantage.
• Those with spinal hardware, severe arthritis, scoliosis or prior vertebral fractures, where DEXA reads can be distorted.
• People who are bedridden or immobilised and cannot easily access fixed DEXA equipment.
• Younger adults for whom minimising radiation is a priority (the proposed parameters reference ages 21 and over).
• Anyone facing long waits or limited access to a DEXA appointment who wants an earlier, radiation-free baseline.

REMS is also being studied across a wide weight range (the proposed parameters cite 30 kg to 250 kg) and in metabolic conditions — for instance, one review noted that 47.0% of women with type 2 diabetes were classified osteoporotic by REMS versus 28.0% by DEXA Diagnostics, 2023, a group where standard DEXA can underestimate risk. If you are weighing up your options, our bone health assessment and BioDensity pages explain what an SMB screening involves, and our assessment days page shows how we run mobile pop-up screening across the UK.

How do you use REMS results — what happens next?

A REMS result is a starting point, not a verdict. You will receive a bone density reading and a T-score for the spine and hip, and — where applicable — a Fragility Score indicating estimated fracture risk. The right next step depends on what those numbers show.

• If your result is reassuring, you have a radiation-free baseline to re-measure against in future — useful through menopause, on weight-loss medication, or simply as you age.
• If your result suggests low bone mass or raised fracture risk, the appropriate path in the UK is to discuss it with your GP, who may arrange a diagnostic DEXA and consider fracture-risk tools and treatment in line with national guidance.
• Either way, the result should drive action — on exercise, protein, calcium and vitamin D, and clinical follow-up where needed — rather than sit in a drawer.

Because the changes that matter to bone happen slowly, the real value is in catching a trend early, while prevention is most effective. A radiation-free scan makes that repeat measurement practical.

You can book a screening with Screen My Bones, see where we screen across the UK, or learn more about our team and clinical approach.

---

This article is part of our screening technology series. If you're tracking bone health while on weight-loss injections, see our guide on Ozempic and bone loss and the wider weight-loss medications series.